Maravai Price To Operating Cash Flows Ratio from 2010 to 2024

MRVI Stock  USD 5.66  0.11  1.91%   
Maravai Lifesciences' Price To Operating Cash Flows Ratio is increasing with slightly volatile movements from year to year. Price To Operating Cash Flows Ratio is estimated to finish at 7.19 this year. For the period between 2010 and 2024, Maravai Lifesciences, Price To Operating Cash Flows Ratio quarterly trend regression had median of (14,278) and r-value of  0.85. View All Fundamentals
 
Price To Operating Cash Flows Ratio  
First Reported
2010-12-31
Previous Quarter
6.84552423
Current Value
7.19
Quarterly Volatility
7.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Maravai Lifesciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Maravai Lifesciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 33.8 M, Interest Expense of 33.9 M or Selling General Administrative of 103.3 M, as well as many indicators such as Price To Sales Ratio of 2.84, Dividend Yield of 0.0157 or PTB Ratio of 1.97. Maravai financial statements analysis is a perfect complement when working with Maravai Lifesciences Valuation or Volatility modules.
  
Check out the analysis of Maravai Lifesciences Correlation against competitors.

Latest Maravai Lifesciences' Price To Operating Cash Flows Ratio Growth Pattern

Below is the plot of the Price To Operating Cash Flows Ratio of Maravai Lifesciences Holdings over the last few years. It is Maravai Lifesciences' Price To Operating Cash Flows Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Maravai Lifesciences' overall financial position and show how it may be relating to other accounts over time.
Price To Operating Cash Flows Ratio10 Years Trend
Slightly volatile
   Price To Operating Cash Flows Ratio   
       Timeline  

Maravai Price To Operating Cash Flows Ratio Regression Statistics

Arithmetic Mean(8,555)
Coefficient Of Variation(84.79)
Mean Deviation6,867
Median(14,278)
Standard Deviation7,254
Sample Variance52.6M
Range14.4K
R-Value0.85
Mean Square Error15.8M
R-Squared0.72
Significance0.000061
Slope1,378
Total Sum of Squares736.7M

Maravai Price To Operating Cash Flows Ratio History

2024 7.19
2023 6.85
2022 3.51
2021 13.05
2020 17.81
2019 119.63

About Maravai Lifesciences Financial Statements

Investors use fundamental indicators, such as Maravai Lifesciences' Price To Operating Cash Flows Ratio, to determine how well the company is positioned to perform in the future. Although Maravai Lifesciences' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Price To Operating Cash Flows Ratio 6.85  7.19 

Currently Active Assets on Macroaxis

When determining whether Maravai Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Maravai Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Maravai Lifesciences Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Maravai Lifesciences Holdings Stock:
Check out the analysis of Maravai Lifesciences Correlation against competitors.
You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Maravai Lifesciences. If investors know Maravai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Maravai Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.33)
Earnings Share
(1.67)
Revenue Per Share
2.044
Quarterly Revenue Growth
(0.03)
Return On Assets
(0.02)
The market value of Maravai Lifesciences is measured differently than its book value, which is the value of Maravai that is recorded on the company's balance sheet. Investors also form their own opinion of Maravai Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Maravai Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Maravai Lifesciences' market value can be influenced by many factors that don't directly affect Maravai Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Maravai Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Maravai Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Maravai Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.